KemPharm (NASDAQ: KMPH)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.050 | -0.050 | 0.0000 | ||||
REV | 3.060M | 3.965M | 905.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of KemPharm (NASDAQ: KMPH) through any online brokerage.
Other companies in KemPharm’s space includes: Satsuma Pharmaceuticals (NASDAQ:STSA), Marinus Pharma (NASDAQ:MRNS), Harrow Health (NASDAQ:HROW), Anebulo Pharmaceuticals (NASDAQ:ANEB) and Endo International (NASDAQ:ENDP).
The latest price target for KemPharm (NASDAQ: KMPH) was reported by HC Wainwright & Co. on Monday, January 31, 2022. The analyst firm set a price target for 11.00 expecting KMPH to rise to within 12 months (a possible 136.05% upside). 1 analyst firms have reported ratings in the last year.
The stock price for KemPharm (NASDAQ: KMPH) is $4.66 last updated June 29, 2022, 8:00 PM UTC.
There are no upcoming dividends for KemPharm.
KemPharm’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for KemPharm.
KemPharm is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.